Clinical trial
A Multicenter, Open Phase I Clinical Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-1826 for Injection in Patients With Advanced Solid Tumors
NCT06094556 is registered in ClinicalTrials.gov with Suzhou Suncadia Biopharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open Phase I Clinical Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-1826 for Injection in Patients With Advanced Solid Tumors
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 25, 2023
- Completion date
- July 31, 2027
- Enrollment
- 240 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors